Literature DB >> 24696834

Prognostic significance of TP53 expression for patients with hepatocellular carcinoma: a meta-analysis.

Ping Zhan1, Ya-Nan Ji1.   

Abstract

BACKGROUND: Various studies evaluated the relationship between p53 expression and the clinical outcome in patients with hepatocellular carcinoma (HCC), but yielded conflicting results.
METHODS: Electronic databases updated to Dec 2013 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between p53 expression and survival of patients with HCC. Survival data were aggregated and quantitatively analyzed.
RESULTS: We performed a meta-analysis of 24 studies that evaluated the correlation between p53 expression and survival in patients with HCC. Combined hazard ratios (HRs) suggested that p53 expression had an unfavorable impact on overall survival (OS) [HR =1.64, 95% confidence interval (CI): 1.40-1.85], and disease free survival (DFS) (HR =1.57, 95% CI: 1.26-1.87) in patients with HCC.
CONCLUSIONS: p53 expression indicates a poor prognosis for patients with HCC.

Entities:  

Keywords:  TP53; expression; hepatocellular carcinoma (HCC); meta-analysis; prognosis

Year:  2014        PMID: 24696834      PMCID: PMC3954998          DOI: 10.3978/j.issn.2304-3881.2014.01.03

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


  41 in total

1.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

Authors:  M K Parmar; V Torri; L Stewart
Journal:  Stat Med       Date:  1998-12-30       Impact factor: 2.373

2.  Risk of venous thromboembolism with the erythropoiesis-stimulating agents (ESAs) for the treatment of cancer-associated anemia: a meta-analysis of randomized control trials.

Authors:  Ping Zhan; Qin Wang; Qian Qian; Li-Ke Yu
Journal:  Chin Clin Oncol       Date:  2012-12

3.  Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma.

Authors:  R-H Yuan; Y-M Jeng; H-L Chen; P-L Lai; H-W Pan; F-J Hsieh; C-Y Lin; P-H Lee; H-C Hsu
Journal:  J Pathol       Date:  2006-08       Impact factor: 7.996

4.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

5.  Operating characteristics of a rank correlation test for publication bias.

Authors:  C B Begg; M Mazumdar
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

6.  Tumour staging, morphology and p53 overexpression concur in predicting survival in hepatocellular carcinoma.

Authors:  S Gianni; A Cecchetto; G Altavilla; R Ragazzi; M Bertazzo; M De Giorgio; A Baldan; S Fagiuoli; F Farinati
Journal:  J Intern Med       Date:  2005-04       Impact factor: 8.989

7.  Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma.

Authors:  Rong-Ping Guo; Chong Zhong; Ming Shi; Chang-Qing Zhang; Wei Wei; Ya-Qi Zhang; Jin-Qing Li
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-09       Impact factor: 4.553

8.  P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection.

Authors:  Lun-Xiu Qin; Zhao-You Tang; Zeng-Chen Ma; Zhi-Quan Wu; Xin-Da Zhou; Qing-Hai Ye; Yuan Ji; Li-Wen Huang; Hu-Liang Jia; Hui-Chuan Sun; Lu Wang
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

9.  Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens.

Authors:  S P Dowell; P O Wilson; N W Derias; D P Lane; P A Hall
Journal:  Cancer Res       Date:  1994-06-01       Impact factor: 12.701

10.  A morpho-molecular prognostic model for hepatocellular carcinoma.

Authors:  S Srivastava; K F Wong; C W Ong; C Y Huak; K G Yeoh; M Teh; J M Luk; M Salto-Tellez
Journal:  Br J Cancer       Date:  2012-06-19       Impact factor: 7.640

View more
  12 in total

1.  Musashi-2 promotes hepatitis Bvirus related hepatocellular carcinoma progression via the Wnt/β-catenin pathway.

Authors:  Ming-Hai Wang; Shi-Yong Qin; Shu-Guang Zhang; Guang-Xin Li; Zhen-Hai Yu; Kun Wang; Bin Wang; Mu-Jian Teng; Zhi-Hai Peng
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

2.  Downregulation of KIF1B mRNA in hepatocellular carcinoma tissues correlates with poor prognosis.

Authors:  Song-Zhu Yang; Jian-Tao Wang; Wei-Wei Yu; Qing Liu; Yan-Fang Wu; Shu-Guang Chen
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

3.  Genome-wide association study identified PLCE1- rs2797992 and EGFR- rs6950826 were associated with TP53 expression in the HBV-related hepatocellular carcinoma of Chinese patients in Guangxi.

Authors:  Xiwen Liao; Chuangye Han; Wei Qin; Xiaoguang Liu; Long Yu; Sicong Lu; Zhiwei Chen; Guangzhi Zhu; Hao Su; Zengnan Mo; Xue Qin; Tao Peng
Journal:  Am J Transl Res       Date:  2016-04-15       Impact factor: 4.060

4.  Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.

Authors:  Sadakatsu Ikeda; Jordan S Lim; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2018-02-26       Impact factor: 6.261

5.  Genomic Landscape of HCC.

Authors:  Adeniji Nia; Renumathy Dhanasekaran
Journal:  Curr Hepatol Rep       Date:  2020-11-10

6.  Prognostic significance of E-cadherin expression in hepatocellular carcinoma: a meta-analysis.

Authors:  Jiang Chen; Jie Zhao; Rui Ma; Hui Lin; Xiao Liang; Xiujun Cai
Journal:  PLoS One       Date:  2014-08-05       Impact factor: 3.240

7.  Cytoplasmic and/or nuclear expression of β-catenin correlate with poor prognosis and unfavorable clinicopathological factors in hepatocellular carcinoma: a meta-analysis.

Authors:  Jiang Chen; Jinghua Liu; Renan Jin; Jiliang Shen; Yuelong Liang; Rui Ma; Hui Lin; Xiao Liang; Hong Yu; Xiujun Cai
Journal:  PLoS One       Date:  2014-11-17       Impact factor: 3.240

8.  SESN2 correlates with advantageous prognosis in hepatocellular carcinoma.

Authors:  Shaosen Chen; Weigang Yan; Weiya Lang; Jing Yu; Li Xu; Xinyu Xu; Yunlong Liu; Hongguang Bao
Journal:  Diagn Pathol       Date:  2017-01-24       Impact factor: 2.644

9.  PLCE1 polymorphisms and expression combined with serum AFP level predicts survival of HBV-related hepatocellular carcinoma patients after hepatectomy.

Authors:  Xiwen Liao; Chuangye Han; Wei Qin; Xiaoguang Liu; Long Yu; Guangzhi Zhu; Tingdong Yu; Sicong Lu; Hao Su; Zhen Liu; Zhiwei Chen; Chengkun Yang; Ketuan Huang; Zhengtao Liu; Yu Liang; Jianlu Huang; Jiahong Dong; Lequn Li; Xue Qin; Xinping Ye; Kaiyin Xiao; Minhao Peng; Tao Peng
Journal:  Oncotarget       Date:  2017-04-25

10.  N6-methyladenosine associated prognostic model in hepatocellular carcinoma.

Authors:  Hanchun Huang; Yi Bai; Xin Lu; Yiyao Xu; Haitao Zhao; Xinting Sang
Journal:  Ann Transl Med       Date:  2020-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.